openPR Logo
Press release

High Potency Active Pharmaceutical Ingredient (HPAPI) Market to Reach US$25.1 bn by 2023 as Oncology Therapeutics Advance

06-19-2017 04:19 PM CET | Health & Medicine

Press release from: TMR - Research Reports

High Potency Active Pharmaceutical Ingredient (HPAPI) Market

Development of Targeted Therapeutic Drugs Drives Global HPAPI Market

The booming oncology research and rising cases of cancer, diabetes, and other cardiovascular diseases have created a sizeable demand for dedicated treatments, thereby driving the high potency active pharmaceutical ingredient (HPAPI) market. The HPAPI market stood at a valuation of US$2.64 bn in 2014. The cost containment strategies adopted by companies through outsourcing are favoring market growth. This has brought down the cost of drugs drastically, making them affordable to a larger audience. The positive result of this trend is seen on the increased focus of companies on drug development and commercialization. As a result of these favorable trends, the HPAPI market is projected to be worth US$25.11 bn by 2023. Between 2015 and 2023, the market is expected to expand at a CAGR of 8.3%.

Read the Upcoming Trends and Global Analysis for High Potency Active Pharmaceutical Ingredient (HPAPI) Market: http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

A promising pipeline of targeted therapeutic drugs will also help the market progress in the coming years. These drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. These positive perceptions surrounding HPAPIs combined with the near-expiration dates of blockbuster drugs, which will offer several generic drug manufacturers a chance to offer affordable drugs, will further the market’s growth. Consistent research and development to mimic branded drugs will create alternative and cost-effective treatments for patients across the globe, thereby augmenting the growth rate of the market.

Emerging Nations in Asia Pacific Becoming Hubs of Generic Drug Manufacturing, to Aid HPAPI Market Growth

Asia Pacific is the expected to be the most lucrative market for high potency active pharmaceutical ingredients due to the soaring contract manufacturing activities in the region. Analysts predict that China will surpass Japan’s current share of 40% in the Asia Pacific market by the end of 2025. This change will be a result of low labor costs in China, well-equipped manufacturing plants, and supportive foreign exchange policies.

India will also be an upcoming high potency active pharmaceutical ingredients market due to the growing concentration of pharmaceutical manufacturing activities in the country. In the forecast period, the country is expected to be the hub for generic drug manufacturing. The growing investments by key players in India are also anticipated to boost this market in the near future. During the forecast period of 2015 to 2023, the Asia Pacific HPAPI market is expected to rise at a CAGR of 10.1%.

Oncology Drugs Show Maximum Demand

The oncology drugs segment has been the leading segment of the global high potency active pharmaceutical ingredient market. This segment is expected to expand at CAGR of 8.3% during the forecast period. The introduction of innovative drugs is the primary growth driver for the oncology segment. Analysts predict that the patent expiry of blockbuster drugs such as Herceptin, Rituxan, and Humira will pave the way for generic drug manufacturers, thereby making these drugs affordable to a wide number of patients.

Request a sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Some of the leading players operating in the global high potency active pharmaceutical ingredient market are WuXi AppTec, Sigma-Aldrich Co. LLC, Pfizer, Inc., Sandoz International GmbH, Novasep, Lonza Group, Dr. Reddy's Laboratories, Cambrex Corporation, and Alkermes plc. The fragmented nature of this market will result in strategies to acquire and merge with regional players to gain the first-mover advantage.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release High Potency Active Pharmaceutical Ingredient (HPAPI) Market to Reach US$25.1 bn by 2023 as Oncology Therapeutics Advance here

News-ID: 585833 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HPAPI

HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report